Engineered immune cells take on deadly brain tumors
NCT ID NCT06355908
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a personalized cell therapy called IL13Rα2 CAR-T for people with recurrent grade 4 glioma, an aggressive brain cancer. The treatment involves collecting a patient's immune cells, engineering them to target a protein on tumor cells, and infusing them back into the brain. The main goal is to check safety, but researchers will also look for signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IL13Rα2-targeted CAR-T cells
What this could lead to
If successful, this could point toward a new treatment option for recurrent grade 4 glioma, a brain cancer with few effective therapies.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so it may not show clear benefit. The treatment is suspended, and there are risks like brain inflammation or other serious side effects from CAR-T therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital
Beijing, China